{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:30:40Z","timestamp":1773930640826,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40121-025-01228-w","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T11:17:14Z","timestamp":1760440634000},"page":"2763-2783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Symptom Alleviation\/Resolution and Returns to Usual Health\/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05438602","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6278-4969","authenticated-orcid":false,"given":"Ruth","family":"Mokgokong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3130-2818","authenticated-orcid":false,"given":"Paul","family":"Cislo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Tudone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-0748","authenticated-orcid":false,"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"20","key":"1228_CR1","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1001\/jama.2021.7212","volume":"325","author":"J Abbasi","year":"2021","unstructured":"Abbasi J. Researchers tie severe immunosuppression to chronic COVID-19 and virus variants. JAMA. 2021;325(20):2033\u20135. https:\/\/doi.org\/10.1001\/jama.2021.7212.","journal-title":"JAMA"},{"issue":"6","key":"1228_CR2","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"L Corey","year":"2021","unstructured":"Corey L, Beyrer C, Cohen MS, et al. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385(6):562\u20136. https:\/\/doi.org\/10.1056\/NEJMsb2104756.","journal-title":"N Engl J Med"},{"key":"1228_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100747","author":"RA Evans","year":"2023","unstructured":"Evans RA, Dube S, Lu Y, et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. The Lancet Regional Health. 2023. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100747.","journal-title":"The Lancet Regional Health"},{"issue":"Supplement_1","key":"1228_CR4","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/infdis\/jiad181","volume":"228","author":"A Antinori","year":"2023","unstructured":"Antinori A, Bausch-Jurken M. The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future. J Infect Dis. 2023;228(Supplement_1):S4\u201312. https:\/\/doi.org\/10.1093\/infdis\/jiad181.","journal-title":"J Infect Dis"},{"issue":"15","key":"1228_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397\u2013408. https:\/\/doi.org\/10.1056\/NEJMoa2118542.","journal-title":"N Engl J Med"},{"key":"1228_CR6","unstructured":"U.S. Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION: PAXLOVID\u2122 (nirmatrelvir tablets; ritonavir tablets), co-packaged for oral use. 2025. Updated 12-Feb-2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217188s010lbl.pdf. Accessed 19 Feb 2025."},{"key":"1228_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00221-X","author":"E Weinstein","year":"2025","unstructured":"Weinstein E, Paredes R, Gardner A, et al. Extended nirmatrelvir\u2013ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2025. https:\/\/doi.org\/10.1016\/S1473-3099(25)00221-X.","journal-title":"Lancet Infect Dis"},{"issue":"16","key":"1228_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jama.2023.19542","volume":"330","author":"KW Chew","year":"2023","unstructured":"Chew KW, Malani PN, Gandhi RT. COVID-19 therapeutics for nonhospitalized patients\u2014updates and future directions. JAMA. 2023;330(16):1519\u201320. https:\/\/doi.org\/10.1001\/jama.2023.19542.","journal-title":"JAMA"},{"key":"1228_CR9","unstructured":"Infectious Diseases Society of America. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. 2023. Updated 04-Jun-2025. Available from: https:\/\/www.idsociety.org\/COVID19guidelines. Accessed 13 Jun 2025."},{"key":"1228_CR10","unstructured":"US Centers for Disease Control and Prevention. Underlying Conditions and the Higher Risk for Severe COVID-19. 2025. Updated 06-Feb-2025. Available from: https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html. Accessed 12 Jun 2025."},{"key":"1228_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae551","author":"J Hammond","year":"2019","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Alleviation of Coronavirus Disease, et al. Symptoms and reduction in healthcare utilization among high-risk patients treated with nirmatrelvir\/ritonavir (NMV\/R): a phase 3 randomized trial. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciae551.","journal-title":"Clin Infect Dis"},{"key":"1228_CR12","unstructured":"Pfizer\u2019s PAXLOVID\u2122 Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 [press release]. 25-May-2023. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-paxlovidtm-receives-fda-approval-adult-patients. Accessed 21 Feb 2025."},{"key":"1228_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf449","author":"W Ansari","year":"2025","unstructured":"Ansari W, Coetzer H, Gebo KA, et al. Patient-reported outcomes of nirmatrelvir treatment for high-risk, nonhospitalized adults with symptomatic COVID-19. Open Forum Infect Dis. 2025. https:\/\/doi.org\/10.1093\/ofid\/ofaf449.","journal-title":"Open Forum Infect Dis"},{"issue":"731","key":"1228_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk1599","volume":"16","author":"Y Li","year":"2024","unstructured":"Li Y, Choudhary MC, Regan J, et al. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci Transl Med. 2024;16(731):eadk1599.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1228_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s15010-023-02138-0","volume":"52","author":"V G\u00f6tz","year":"2024","unstructured":"G\u00f6tz V, Math\u00e9 P, Agarwal P, et al. Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era. Infection. 2024;52(3):923\u201333. https:\/\/doi.org\/10.1007\/s15010-023-02138-0.","journal-title":"Infection"},{"issue":"7","key":"1228_CR16","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/jac\/dkad144","volume":"78","author":"S Huygens","year":"2023","unstructured":"Huygens S, Gharbharan A, Serroukh Y, et al. High-titer convalescent plasma plus nirmatrelvir\/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients. J Antimicrob Chemother. 2023;78(7):1644\u20138. https:\/\/doi.org\/10.1093\/jac\/dkad144.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1228_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/23744235.2023.2223274","volume":"55","author":"AL Lindahl","year":"2023","unstructured":"Lindahl AL, Ahava MJ, Haukip\u00e4\u00e4 M, et al. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir\/ritonavir courses: a case report. Infect Dis (Lond). 2023;55(8):585\u20139. https:\/\/doi.org\/10.1080\/23744235.2023.2223274.","journal-title":"Infect Dis (Lond)"},{"issue":"8","key":"1228_CR18","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.cmi.2024.04.009","volume":"30","author":"SE Meijer","year":"2024","unstructured":"Meijer SE, Paran Y, Belkin A, et al. Persistent COVID-19 in immunocompromised patients-Israeli society of infectious diseases consensus statement on diagnosis and management. Clin Microbiol Infect. 2024;30(8):1012\u20137. https:\/\/doi.org\/10.1016\/j.cmi.2024.04.009.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"1228_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s12325-024-03043-0","volume":"42","author":"CD Spinner","year":"2025","unstructured":"Spinner CD, Bell S, Einsele H, et al. Is COVID-19 still a threat? An expert opinion review on the continued healthcare burden in immunocompromised individuals. Adv Ther. 2025;42(2):666\u2013719. https:\/\/doi.org\/10.1007\/s12325-024-03043-0.","journal-title":"Adv Ther"},{"issue":"7","key":"1228_CR20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jval.2021.01.005","volume":"24","author":"A Gnanasakthy","year":"2021","unstructured":"Gnanasakthy A, Barrett A, Norcross L, et al. Use of patient and investigator global impression scales: a review of Food and Drug Administration\u2013approved labeling, 2009 to 2019. Value Health. 2021;24(7):1016\u201323. https:\/\/doi.org\/10.1016\/j.jval.2021.01.005.","journal-title":"Value Health"},{"key":"1228_CR21","unstructured":"US Food and Drug Administration. Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment: Guidance for Industry. 2024. Available from: https:\/\/www.fda.gov\/media\/167275\/download. Accessed 10 Feb 2025."},{"issue":"282","key":"1228_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u201381. https:\/\/doi.org\/10.2307\/2281868.","journal-title":"J Am Stat Assoc"},{"key":"1228_CR23","unstructured":"Weir CJ, A. BMI Classification Percentile And Cut Off Points. StatPearls [Internet]. 2025. Updated 26-Jun-2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541070\/. Accessed 28 Jan 2025."},{"issue":"1","key":"1228_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/v15010167","volume":"15","author":"S Chatterjee","year":"2023","unstructured":"Chatterjee S, Bhattacharya M, Nag S, et al. A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses. 2023;15(1):167. https:\/\/doi.org\/10.3390\/v15010167.","journal-title":"Viruses"},{"key":"1228_CR25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.15585\/mmwr.mm7342a1","volume":"73","author":"KC Ma","year":"2024","unstructured":"Ma KC, Castro J, Lambrou AS, et al. Genomic surveillance for SARS-CoV-2 variants: circulation of omicron XBB and JN.1 lineages\u2014United States, May 2023\u2013September 2024. MMWR Morb Mortal Wkly Rep. 2024;73:938\u201345.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"1228_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf055","volume":"12","author":"M Vergouwe","year":"2025","unstructured":"Vergouwe M, Birnie E, van Veelen S, et al. A longitudinal description of the health-related quality of life among individuals at high risk after SARS-CoV-2 infection: a Dutch multicenter observational cohort study. Open Forum Infect Dis. 2025;12(2):ofaf055. https:\/\/doi.org\/10.1093\/ofid\/ofaf055.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"1228_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac618","volume":"9","author":"C Moser","year":"2022","unstructured":"Moser C, Li JZ, Eron JJ, et al. Predictors of SARS-CoV-2 RNA from nasopharyngeal swabs and concordance with other compartments in nonhospitalized adults with mild to moderate COVID-19. Open Forum Infect Dis. 2022;9(11):ofac618. https:\/\/doi.org\/10.1093\/ofid\/ofac618.","journal-title":"Open Forum Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01228-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01228-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01228-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:03:50Z","timestamp":1762844630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01228-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01228-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ruth Mokgokong is an employee and a minority shareholder of Pfizer, which funded this study. Paul Cislo is an employee and a minority shareholder of Pfizer, which funded this study. Elena Tudone is an employee and a minority shareholder of Pfizer, which funded this study. Edward Weinstein is an employee and a minority shareholder of Pfizer, which funded this study. Joseph C. Cappelleri is an employee and a minority shareholder of Pfizer, which funded this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics approval for the EPIC-IC protocol, amendments, and other relevant documents was granted by the appropriate institutional review boards and ethics committees (Supplementary Materials), as documented in Weinstein et al., 2025 [\n                      \n                      ]. The study did not have a \u2018master\u2019 ethics committee or a main center; the principal investigator who signed the clinical study report was Dr. Roger Paredes, Hospital Germans Trias i Pujol, Spain. Participants provided written informed consent before enrolling in the study. The study was conducted in accordance with consensus ethical principles, including those in the Helsinki Declaration of 1964 and the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines; with applicable International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) guidelines for Good Clinical Practice; and with applicable laws and regulations, including applicable privacy laws.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}